1 / 22

Schema di chemioterapia da associare a trastuzumab e valutazione della risposta

Schema di chemioterapia da associare a trastuzumab e valutazione della risposta. Laura Biganzoli. U.O. Oncologia Medica “Sandro Pitigliani” Ospedale di Prato Istituto Toscano Tumori. Caso clinico. Donna di 50 anni ECOG PS0 Nega comorbidita’

Download Presentation

Schema di chemioterapia da associare a trastuzumab e valutazione della risposta

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Schema di chemioterapia da associare a trastuzumab e valutazione della risposta Laura Biganzoli U.O. Oncologia Medica “Sandro Pitigliani” Ospedale di Prato Istituto Toscano Tumori

  2. Caso clinico • Donna di 50 anni • ECOG PS0 • Nega comorbidita’ • Autopalpazione nodulo mammella dx  mammografia: nodulo QSE di 5 cm, Ln ascellare dx: C5; agobiopsia mammaria: B5 CDIS -Carcinoma duttale infiltrante G3, ER 50%, PgR40%, Ki67 30%, HER2 3+; RMN lesione unifocale • Non fattibile intervento chirurgico conservativo • TC Torace-addome e scintigrafia ossea = negative per M+; ECO cuore=N

  3. Opzioni terapeutiche • Si propone alla paziente trattamento neoadiuvante contenente trastuzumab • antraciclina taxano + trastuzumab • antraciclina + trastuzumab  taxano + trastuzumab • chemioterapia senza antraciclina + trastuzumab • nessuna chemioterapia ma “dual HER2 targeting”

  4. ACx4 ACx4 ACx4 Sx Sx Tx4 Sx Tx4 NSABP B-27 Arm A Arm B Arm C T, docetaxel Sx, surgery % pCR 13.7 25.6 p<.001 Overall survival Bear et al. J Clin Oncol 2006

  5. MDACC trial T, paclitaxel; H, trastuzumab Buzdar et al. Clin Cancer Res 2007 Randomized study population

  6. NOAH: Phase III, Open-Label Trial of Neoadjuvant Trastuzumab Gianni et al. Lancet. 2010

  7. Cardiac safety MDACC • No clinical cardiac dysfunction • Exact binomial 95% CI of the probability • of cardiac failure = 0% to 7.8% Buzdar et al. Clin Cancer Res 2007 NOHA Median follow-up 3.2 yrs Gianni et al. Lancet. 2010

  8. Neo-ALTTO NeoSphere pCR rates Baselga et al. Cancer Res 2010 Gianni et al. Cancer Res 2010 pCR rate in NOHA= 43%

  9. NeoSphere Gianni et al. Cancer Res 2010 Chang et al. Chang et al. ASCO 2011

  10. Mia opinione • Chemioterapia contenente antracicline e taxani = standard • Mancano dati di safety a lungo termine per somministrate trastuzumab in associazione ad antracicline

  11. La paziente e’ stata trattata con AC x 4  docetaxel x 4 + trastuzumab • Sottoposta a quadrantectomia + svuotamento del cavo ascellare. EI: CDIS. Infiltrazione cancerigna di 1/16 ln esaminati • Definiamo la risposta come pCR? • Si • No

  12. The literature has included several definitions of pCR as well as several attempts to design a sliding scale of pathologic response in order to avoid the limitations of a dichotomous endpoint (overly simplistic– residual disease Δ from near pCR to frank resistance) Sahoo and Lester. Arch Pathol Lab Med 2009

  13. Definition of pCR • NSABP B27: Surgical specimens with no invasive cancer in the breast were considered to be a pathologic complete response (pCR) Mazouni et al. J Clin Oncol 2007

  14. Outcome according to the pathological status of the breast and the axilla • When there is no residual invasive cancer in the breast, the number of involved axillary lymph nodes is inversely related to survival (NSABP-B27) Bear et al. J Clin Oncol 2006 • Patients who convert to node-negative status after treatment have excellent survival, even if there is residual disease (RD) in the breast Hennessy et al. J Clin Oncol 2005

  15. Neo-ALTTO: pCR and total pCR Total pCR= breast + axilla

  16. La risposta al trattamento neoadiuvante puo’ essere definita pCR

  17. Back up

  18. yes unk no

More Related